The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?

ABSTRACT: The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a paradigm shift in melanoma treatment, to surmount the therapeutic impasses linked to the resistance, is an important ongoing challenge.This review outlines the multifaceted interplay between microphthalmia-associated transcription factor (MITF), a major determinant of the biology of melanoma cells, and the immune system. In melanomas, MITF functions downstream oncogenic pathways and microenvironment stimuli that restrain the immune responses. We highlight how MITF, by controlling differentiatio

SUBMITTER: Ballotti R 

PROVIDER: S-EPMC7718690 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature